A Phase 3 interventional study of Comparator: losartan +/- HCTZ and Comparator: Placebo in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.
Among the 65 studies testing losartan in Hypertension, this one is the 17th largest by enrollment, is one of 3 that started in 2006, is one of 17 in phase 3, and was the 6th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
Jing Liu · Sites in China
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 18 · Phase 4 26
First in 1990; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 65 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
26 studies in Hypertension by Organon & Co.: none open now, none under way, none of them phase 3. Of 26 finished, 15 (58%) have results posted.
Among the 26 studies in Hypertension by Organon & Co., this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2006, is one of 16 in phase 3, and was the 4th registered.
Organon & Co.’s Hypertension studies by the year they started, since 1995.
3 of the studies testing losartan in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
| NCT04715568University of California, San FranciscoSecondhand Tobacco Smoke and Cardiovascular Disease | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing losartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 26 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 16-week study to evaluate high systolic and diastolic blood pressure following treatment in obese, hypertensive, adult patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Losartan
Drug: Comparator: losartan +/- HCTZ
Placebo
Drug: Comparator: Placebo
Drug pages: Losartan · Hydrochlorothiazide
Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8
Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
Time frame: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8
Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
Time frame: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
Time frame: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12
Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
Time frame: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16
Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
Time frame: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16
Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
Time frame: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Patients were recruited at 51 sites in the United States. Prime Therapy Period: April 2006 to February 2007
| Milestone | Losartan | Placebo |
|---|---|---|
| Started | 127 | 134 |
| Completed | 105 | 105 |
| Not completed | 22 | 29 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lack of efficacy | 3 | 11 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 3 | 8 |
| Withdrew: Other | 7 | 3 |
Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
| mm Hg | Losartan | Placebo |
|---|---|---|
| Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 | -12.1 ± 1.2 | -6.8 ± 1.2 |
Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
| mm Hg | Losartan | Placebo |
|---|---|---|
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8 | -9.7 ± 0.8 | -6.9 ± 0.8 |
Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
| mm Hg | Losartan | Placebo |
|---|---|---|
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | -12.9 ± 0.8 | -7.1 ± 0.8 |
Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
| mm Hg | Losartan | Placebo |
|---|---|---|
| Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 | -16.7 ± 1.3 | -6.8 ± 1.3 |
Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
| mm Hg | Losartan | Placebo |
|---|---|---|
| Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16 | -19.1 ± 1.3 | -6.4 ± 1.3 |
Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.
| mm Hg | Losartan | Placebo |
|---|---|---|
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16 | -14.1 ± 0.9 | -6.0 ± 0.9 |
Collected over Week 0 through Week 16.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Losartan | — | 1/127 (0.8%) | 4/127 (3.1%) |
| Placebo | — | 1/134 (0.7%) | 7/134 (5.2%) |
| Event | Losartan | Placebo |
|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 1/127 | 0/134 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/127 | 1/134 |
| Event | Losartan | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 4/127 | 7/134 |
| Age, Continuous(years) | Losartan | Placebo | Total |
|---|---|---|---|
| Mean | 50.1 ± 10.4 | 51.4 ± 9.7 | 50.8 ± 10.0 |
| Sex: Female, Male(Participants) | Losartan | Placebo | Total |
|---|---|---|---|
| Female | 79 | 77 | 156 |
| Male | 48 | 57 | 105 |
| Race/Ethnicity, Customized(participants) | Losartan | Placebo | Total |
|---|---|---|---|
| Caucasian | 84 | 87 | 171 |
| Black | 22 | 29 | 51 |
| Hispanic American | 20 | 16 | 36 |
| Native American | 0 | 1 | 1 |
| Other | 1 | 1 | 2 |
| Sitting Diastolic Blood Pressure (SiDBP)(mm Hg) | Losartan | Placebo | Total |
|---|---|---|---|
| Mean | 99.1 ± 4.2 | 99.0 ± 4.0 | 99.0 ± 4.1 |
| Sitting Systolic Blood Pressure (SiSBP)(mm Hg) | Losartan | Placebo | Total |
|---|---|---|---|
| Mean | 151.6 ± 8.2 | 152.4 ± 9.0 | 152.0 ± 8.6 |
No study locations are listed for this record.
The record gives a start of Feb 2006, a primary completion of Feb 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Losartan · Hydrochlorothiazide